Tenaya Therapeutics, Inc.
tenayatherapeutics.comWhat Do They Do?
Develops gene therapies and a small-molecule medicine for people with genetic heart conditions and other cardiac, metabolic, muscular and pulmonary diseases.
10-K for FY2025, filed Mar 11, 2026We are a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies…View ↗
We are primarily focused on advancing our clinical-stage gene therapy candidates, TN-201, for MYBPC3-associated hypertrophic cardiomyopathy…View ↗
TN-301 small molecule HDAC6 inhibitor for the potential treatment of HFpEF and other cardiac, muscular or metabolic conditions: We…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 11, 2026
Who Are Their Customers?
Alnylam works with Tenaya to identify and validate cardiovascular gene targets. Alnylam reimburses research work and has rights to develop, manufacture and commercialize products directed to collaboration targets.
10-K for FY2025, filed Mar 11, 2026In March 2026, we entered into a collaboration agreement with Alnylam, pursuant to which both parties agreed to a research collaboration to…View ↗
Together, both parties will nominate an aggregate of 15 targets, align on which targets to move forward into the collaboration and then…View ↗
Under the terms of the collaboration agreement, we granted Alnylam an exclusive, worldwide license, with the right to sublicense, under our…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$43.4MView ↗
- ▲ +86% (Loss)
- vs −$23.3M in Q2 FY2025
-
Jun 29, 2026
Tenaya appointed a new chief financial officer
Eric Hyllengren will also serve as principal financial officer and principal accounting officer.
Sources
8-K, filed Jun 29, 2026
On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) announced that Eric Hyllengren, M.B.A., will join the Company as Chief…View ↗
Research collaboration
The earlier report described pipeline programs from internal work and academic licenses; the latest report adds a cardiovascular gene-target research collaboration with Alnylam, with research costs reimbursed.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 11, 2026Our pipeline includes programs that have emerged from our internal efforts, as well as programs that are based on intellectual property…View ↗
Who Do They Compete With?
Competes with Bristol Myers Squibb, Cytokinetics, Edgewise Therapeutics, Lexicon Pharmaceutical, Imbria Pharmaceutical, Novartis, Eli Lilly, Boehringer Ingleheim, Astra Zeneca, Italfarmaco, Catalyst Pharmaceuticals, Santhera Pharmaceutical, PTC Therapeutics, Sarepta Therapeutics, NS Pharma, Capricor Therapeutics, Avidity Bioscience, Rocket Pharmaceutical, and Lexeo Therapeutics
10-K for FY2025, filed Mar 11, 2026TN-201: We believe the principal competition for TN-201 will be programs that address the underlying genetic cause of MYBPC3-associated…View ↗
Loading...
